These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

135 related items for PubMed ID: 9815954

  • 1. Potential of the histoculture drug-response assay to contribute to cancer patient survival.
    Kubota T, Sasano N, Abe O, Nakao I, Kawamura E, Saito T, Endo M, Kimura K, Demura H, Sasano H.
    Clin Cancer Res; 1995 Dec; 1(12):1537-43. PubMed ID: 9815954
    [Abstract] [Full Text] [Related]

  • 2. [Chemosensitivity test for gastric carcinoma].
    Kubota T.
    Gan To Kagaku Ryoho; 1997 Feb; 24(4):495-500. PubMed ID: 9063490
    [Abstract] [Full Text] [Related]

  • 3. Clinical applications of the histoculture drug response assay.
    Furukawa T, Kubota T, Hoffman RM.
    Clin Cancer Res; 1995 Mar; 1(3):305-11. PubMed ID: 9815986
    [Abstract] [Full Text] [Related]

  • 4. Acquisition of multidrug resistance in recurrent breast cancer demonstrated by the histoculture drug response assay.
    Tanino H, Oura S, Hoffman RM, Kubota T, Furukawa T, Arimoto J, Yoshimasu T, Hirai I, Bessho T, Suzuma T, Sakurai T, Naito Y.
    Anticancer Res; 2001 Mar; 21(6A):4083-6. PubMed ID: 11911296
    [Abstract] [Full Text] [Related]

  • 5. Antitumor effect and survival benefit of chemotherapy for unresectable advanced gastric cancer.
    Kiyohashi A, Kurihara M, Yoshida S, Ohkubo T, Suga S.
    Jpn J Clin Oncol; 1993 Feb; 23(1):41-5. PubMed ID: 8459640
    [Abstract] [Full Text] [Related]

  • 6. Cisplatin sensitivity of ovarian cancer in the histoculture drug response assay correlates to clinical response to combination chemotherapy with cisplatin, doxorubicin and cyclophosphamide.
    Ohie S, Udagawa Y, Kozu A, Komuro Y, Aoki D, Nozawa S, Moossa AR, Hoffman RM.
    Anticancer Res; 2000 Feb; 20(3B):2049-54. PubMed ID: 10928150
    [Abstract] [Full Text] [Related]

  • 7. An anticancer drug sensitivity test to determine the effectiveness of UFT as postoperative adjuvant chemotherapy for patients with stage III colorectal cancer.
    Isogai A, Nagaya M, Matsuoka H, Watanabe T, Tsukikawa S, Kubota S.
    Surgery; 2007 Nov; 142(5):741-8. PubMed ID: 17981195
    [Abstract] [Full Text] [Related]

  • 8. Multicentre randomised study of adjuvant chemotherapy with mitomycin C and tegafur or tegafur-uracil in gastric cancer.
    Arima S, Ohsato K, Hisatsugu T, Shimura H.
    Eur J Surg; 1994 Apr; 160(4):227-32. PubMed ID: 8049313
    [Abstract] [Full Text] [Related]

  • 9. [Efficacy of UFT in advanced gastric carcinoma under comparative study of MMC + UFT and MMC + tegafur therapies].
    Inoue Y, Nasu H, Nakamura J, Arakawa H, Masamune O, Yamada N, Furuya M, Ookubo M, Mukojima T, Koizumi R.
    Gan To Kagaku Ryoho; 1989 Nov; 16(11):3567-72. PubMed ID: 2510604
    [Abstract] [Full Text] [Related]

  • 10. [Randomized controlled trial of MMC + UFT and MMC + 5-FU therapy in advanced gastric cancer].
    Sasagawa T, Ho N, Endo T, Sekine T, Sugiyama K, Tomidokoro T, Hatakeyama S, Togashi M, Onuki K, Katagiri J.
    Gan To Kagaku Ryoho; 1994 Jul; 21(8):1179-85. PubMed ID: 8031159
    [Abstract] [Full Text] [Related]

  • 11. Evaluation of optimal drug concentration in histoculture drug response assay in association with clinical efficacy for head and neck cancer.
    Hasegawa Y, Goto M, Hanai N, Ijichi K, Adachi M, Terada A, Hyodo I, Ogawa T, Furukawa T.
    Oral Oncol; 2007 Sep; 43(8):749-56. PubMed ID: 17112769
    [Abstract] [Full Text] [Related]

  • 12. Randomized trial of adjuvant chemotherapy with mitomycin, Fluorouracil, and Cytosine arabinoside followed by oral Fluorouracil in serosa-negative gastric cancer: Japan Clinical Oncology Group 9206-1.
    Nashimoto A, Nakajima T, Furukawa H, Kitamura M, Kinoshita T, Yamamura Y, Sasako M, Kunii Y, Motohashi H, Yamamoto S, Gastric Cancer Surgical Study Group, Japan Clinical Oncology Group.
    J Clin Oncol; 2003 Jun 15; 21(12):2282-7. PubMed ID: 12805327
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. A randomized consent design trial of neoadjuvant chemotherapy with tegafur plus uracil (UFT) for gastric cancer--a single institute study.
    Nio Y, Koike M, Omori H, Hashimoto K, Itakura M, Yano S, Higami T, Maruyama R.
    Anticancer Res; 2004 Jun 15; 24(3b):1879-87. PubMed ID: 15274369
    [Abstract] [Full Text] [Related]

  • 15. [The fourth report from Sapporo Tsukisamu Hospital - chemotherapy and its regimen as second choice for patients with early gastric cancer].
    Yamamitsu S, Kimura H, Yamada Y, Inui N, Hiyama S, Hirata K, Kimura Y, Yamaguchi K, Shirasaka T.
    Gan To Kagaku Ryoho; 2007 Oct 15; 34(10):1589-94. PubMed ID: 17940373
    [Abstract] [Full Text] [Related]

  • 16. A phase II study of epirubicin, cisplatin and uracil-tegafur for advanced gastric carcinoma.
    Woo IS, Moon DH, Shim BY, Lee MA, Byun JH, Kim KW, Kang JH, Choi MG, Chung IS, Hong YS, Park SY, Lee KS.
    Jpn J Clin Oncol; 2005 Jan 15; 35(1):13-7. PubMed ID: 15681598
    [Abstract] [Full Text] [Related]

  • 17. Phase II trial of epirubicin, cisplatin, oral uracil and tegafur, and leucovorin in patients with advanced gastric carcinoma.
    Jeen YT, Yoon SY, Shin SW, Kim BS, Mok YJ, Kim CS, Hyun JH, Kim JS, Kim YH.
    Cancer; 2001 Jun 15; 91(12):2288-93. PubMed ID: 11413517
    [Abstract] [Full Text] [Related]

  • 18. Postsurgical sequential methotrexate/5-FU and leucovorin on outpatient basis for advanced colorectal carcinoma.
    Tokunaga Y, Kitaoka A, Yagi T, Tokuka A, Ohsumi K.
    Hepatogastroenterology; 2001 Jun 15; 48(37):128-32. PubMed ID: 11268947
    [Abstract] [Full Text] [Related]

  • 19. [UFT-therapy and UFTM therapy--comparison of survivals in the patients with Borrmann type 4 gastric cancer treated either with UFTM-chemotherapy or operation].
    Suga S, Kimura K, Yokoyama Y.
    Gan To Kagaku Ryoho; 1984 Mar 15; 11(3 Pt 2):769-74. PubMed ID: 6424582
    [Abstract] [Full Text] [Related]

  • 20. A multiple-center phase II study of biweekly oxaliplatin and tegafur-uracil/leucovorin for chemonaive patients with advanced gastric cancer.
    Chen JS, Rau KM, Chen YY, Huang JS, Yang TS, Lin YC, Liau CT, Lee KD, Su YC, Kao RH.
    Cancer Chemother Pharmacol; 2009 Apr 15; 63(5):819-25. PubMed ID: 18663448
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.